Clinical Trial Update: Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the combination of copanlisib and ibrutinib in patients with refractory or recurrent primary central nervous system lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Aliqopa (copanlisib)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) | Phase 1, Phase 2 | Status: COMPLETED